Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,902 |
|
|||||
| News | - | ||||||
| Day High | 0.0749 | Low High |
|||||
| Day Low | 0.06835 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NovelStem International Corp (PK) | NSTM | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.0148 | 24.63% | 0.0749 | 14:27:14 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.06835 | 0.06835 | 0.0749 | 0.0749 | 0.0601 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2 | 1,902 | US$ 0.06835 | US$ 130 | - | 0.06 - 0.2768 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:27:14 | 951 | US$ 0.0749 | USD |
NovelStem International Corp (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 3.51M | 46.88M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NovelStem (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/15/2024 | 13:38 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 1/23/2024 | 16:26 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/19/2023 | 16:24 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/17/2023 | 14:34 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/14/2023 | 13:09 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 7/13/2023 | 16:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 6/28/2023 | 13:46 | Edgar (US Regulatory) | Form 10-12G/A - Registration of securities [Section 12(g)]:.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NSTM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0601 | 0.0749 | 0.0601 | 0.0601 | 501 | 0.0148 | 24.63% |
| 1 Month | 0.0601 | 0.0749 | 0.0601 | 0.0601 | 2,751 | 0.0148 | 24.63% |
| 3 Months | 0.07 | 0.0749 | 0.06 | 0.0600896 | 2,860 | 0.0049 | 7.00% |
| 6 Months | 0.0721 | 0.0855 | 0.06 | 0.0645153 | 10,325 | 0.0028 | 3.88% |
| 1 Year | 0.171 | 0.2768 | 0.06 | 0.1111728 | 11,025 | -0.0961 | -56.20% |
| 3 Years | 0.30 | 0.35 | 0.0325 | 0.2193277 | 26,367 | -0.2251 | -75.03% |
| 5 Years | 0.101 | 0.35 | 0.0325 | 0.1581693 | 32,337 | -0.0261 | -25.84% |
NovelStem (PK) Description
| NovelStem owns a 33% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies. NovelStem recently increased its ownership to 33% from 27.3% based upon completion of an additional $1M investment on top of $3M that was invested prior, for a total investment of $4M in NewStem. NovelStem also has a 50% stake in Netco Partners, which owns the Net Force publishing franchise. NewStem is advancing novel stem-cell-based technology utilized for the development of new diagnostics and therapeutics. The most advanced product of NewStem is a diagnostic predicting patients resistance to cancer therapy, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalems technology-transfer company. NewStems diagnostic solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells & Genetic Research at Hebrew University. NewStem holds the intellectual property, reagents & experience required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity & tumorigenicity. |
